Diabetes mellitus among outpatients receiving clozapine: Prevalence and clinical-demographic correlates

Journal of Clinical Psychiatry

Volumn 66, Issue 7, 2005, Pages 900-906

  Lamberti, J Steven ^a   Costea, G Oana ^a   Olson, David ^a   Crilly, John F ^a   Maharaj, Kumar ^a   Tu, Xin ^a   Groman, Adrienne ^a   Dietz, Marci B ^a   Bushey, Margaret P ^a   Olivares, Telva ^a   Wiener, Karen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; ETHNOLOGY; FAMILY HISTORY; FEMALE; FISHER EXACT TEST; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 22744436502     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0713     Document Type: Article

References (76)

1. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine [letter]. Am J Psychiatry 1994; 151:1395
2. Koval MS, Ramy LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment [letter]. Am J Psychiatry 1994;151:1520-1521
3. Kostakoglu AE, Yazici KM, Erbas T, et al. Ketoacidosis as a side effect of clozapine: a case report. Acta Psychiatr Scand 1996;93:217-218
4. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment [letter]. Am J Psychiatry 1996;153:737-738
5. Koren W, Kreis Y, Duchowiczny K, et al. Lactic acidosis and fatal myocardial infarction due to clozapine. Ann Pharmacother 1997;31:168-170
6. Pierides M. Clozapine monotherapy and ketoacidosis [letter]. Br J Psychiatry 1997;171:90-91
7. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-111
8. Good MI. Lethal interaction of clozapine and buspirone [letter]? Am J Psychiatry 1997;154:1472-1473
9. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998;49:1081-1083
10. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783
11. Thompson J, Chengappa KN, Good CB, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998;13:95-98
12. Brugman NJ, Cohen D, deVries RH. Diabetes mellitus after treatment with clozapine [in Dutch]. Ned Tijdschr Geneeskd 2000;144:437-439
13. Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. Postgrad Med J 1998;74:493-494
14. Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis [letter]. Aust N Z J Psychiatry 1999;33:120-121
15. Colli A, Cocciolo M, Francobandiera G, et al. Diabetic ketoacidosis associated with clozapine treatment [letter]. Diabetes Care 1999;22: 176-177
16. Maule S, Giannella R, Lanzio M, et al. Diabetic ketoacidosis with clozapine treatment [letter]. Diabetes Nutr Metab 1999;12:187-188
17. Mohan D, Gordon H, Hindley NB, et al. Schizophrenia and diabetes mellitus [letter]. Br J Psychiatry 1999;174:180-181
18. Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical anti-psychotic drugs: a report of three cases. Diabet Med 2000;17: 484-486
19. Wehring BA, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000;20:844-847
20. Wu G, Dias P, Wu C, et al. Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:1395-1400
21. Isakov I, Klesmer J, Masand PS. Insulin-resistant hyperglycemia induced by clozapine [letter]. Psychosomatics 2000;41:373-374
22. Littrell KH, Petty RG, Peabody CD, et al. Treatment of preexisting diabetes with olanzapine [letter]. J Clin Psychiatry 2001;62:733-734
23. Avram AM, Patel V, Taylor HC, et al. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001;35: 1381-1387
24. Sauer J, Funnell N, Reveley A. Hyperglycaemia and myoclonus with clozapine. Psychiatr Bull R Coll Psychiatr 2001;25:360-361
25. Nicolai J, Smith SJ, Keunen RW. Simultaneous side effects of both clozapine and valproate [letter]. Intensive Care Med 2001;27:943
26. Wilson DR, D'Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003;59:1-6
27. Lafayette JM, Pirl WF, Henderson DC. Low-dose clozapine and diabetic ketoacidosis. Psychosomatics 2003;44:249-252
28. Kristensen SH, Porksen NK. Clozapine and diabetic ketoacidosis [in Danish]. Ugeskr Laeger 2003;165:475-476
29. Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents [letter]. JAMA 2001;286:2547-2548
30. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998;106:475-477
31. Melkersson KI, Hulting A-L, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999;60:783-791
32. Hägg S, Joelsson L, Mjörndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-299
33. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566
34. Sernyak MJ, Gulanski B, Leslie DL, et al. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry 2003; 64:605-608
35. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-930
36. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-981
37. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001;111:716-723
38. Leonard P, Halley A, Browne S. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Ir Med J 2002;95: 119-120
39. Kivircik BB, Alptekin K, Caliskan S, et al. Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27: 795-799
40. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003;170:157-166
41. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345
42. Wirshing DA, Boyd JA, Meng LR. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865
43. Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002;22:236-243
44. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58:1172-1176
45. Renegold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2001;70:19-26
46. Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164-170
47. Gupta S, Steinmeyer C, Frank B, et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther 2003;10:348-355
48. Lamberti JS, Crilly JF, Maharaj K, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004;65:702-706
49. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296
50. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28:995-1003
51. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
52. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(suppl 2):1-56
53. Powers AC. Diabetes mellitus. In: Braunwald E, Fauci A, Kasper D, et al, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill Publishers; 2001:2109-2137
54. Tanita Corp. of America, Inc. Tanita Body Fat Monitor information page. Available at: www.tanita.com/QuestionsAboutBFMonitor.shtml#5. Accessed Sept 1, 2004
55. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2003;26:21-24
56. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79
57. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835
58. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients [letter]. Lancet 1989;1:495
59. Adams PF, Marano MA. Current Estimates From the National Health Interview Survey, 1994. National Center for Health Statistics. Vital Health Stat 10 1995;193:1-520
60. Citrome LL. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today (Barc) 2004; 40:445-464
61. Freed H, Fortunato E, Ludlum SD, et al. Changes in the glucose tolerance test occurring in schizophrenics during and after insulin shock therapy for schizophrenia. Am J Med 1938;196:36-44
62. Proctor L, Dewan JG, McNeel BH. Variations in the glucose tolerance observations in schizophrenics before and after shock treatment. Am J Psychiatry 1944;100:652-658
63. Braceland JF, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945;102:108-110
64. Freeman H, Zaborenke RN. Relation of changes in carbohydrate metabolism to psychotic states. Arch Neurol Psychiatry 1949;61:569-576
65. Freeman H, Elmadjian F. Carbohydrate and lymphoid studies in schizophrenia. Am J Psychiatry 1950;106:660-667
66. Henneman DH, Altschule MD, Goncz RM. Carbohydrate metabolism in brain disease, pt 2: glucose metabolism in schizophrenic, manic-depressive, and involutional psychoses. AMA Arch Intern Med 1954; 94:402-416
67. Freeman H, Rodnick EH, Shakow D, et al. The carbohydrate tolerance of mentally disturbed soldiers. Psychosom Med 1944;6:311-317
68. Ryan MC, Collins P, Thakore J. Impaired fasting glucose tolerance in first episode, drug naive patients with schizophrenia. Am J Psychiatry 2003;160:284-289
69. Mukherjee SM, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73
70. Allison D, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
71. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses: a comparison between different antipsychotic agents. Psychopharmacology (Berl) 2001;154:205-212
72. Melkersson KI, Khan A, Hilding A, et al. Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol 2001;11:327-332
73. Taylor D, Young C, Esop R, et al. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004;185: 152-156
74. Chrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-1013
75. Deurenberg P. Limitations of the bioelectrical impedance method for the assessment of body fat in severe obesity. Am J Clin Nutr 1996; 64(suppl 3):449-452
76. Citrome L, Jaffe A. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003;37:1849-1857